Clinical Trial Update: Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating augmentation therapy with ARALAST Fraction IV-1 in Alpha 1-antitrypsin deficiency; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• ARALAST Fraction IV-1 (alpha 1-antitrypsin)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 4 | Status: COMPLETED | Results posted: 2011-01-04